Clinical efficacy of apatinib in treating refractory triple-negative advanced breast cancer / 中国肿瘤临床
Chinese Journal of Clinical Oncology
;
(24): 769-772, 2017.
Article
in Chinese
| WPRIM
| ID: wpr-608854
ABSTRACT
Objective:
To evaluate the effectiveness and safety of using apatinib in the treatment of refractory triple-negative advanced breast cancer.Methods:
Eight cases of advanced triple-negative breast cancer patients confirmed via histopathology, who were previously treated with anthracycline, taxane, gemcitabine, capecitabine, and 500 mg/d apatinib in our hospital from July 2015 to November 2016, were retrospectively analyzed. The time of disease progress, effective rate, clinical benefits, and side effects were observed.Results:
Eight patients were administrated with an average of 4 treatment cycles, and the effects were evaluated after 2 weeks. Four patients exhibited partial remission, 3 had a stable disease, and 1 had a progressive disease. The disease control rate was 87.5%, and the median progression free survival was 4.2 months. The main side effects were hand-foot syndrome (3/8), bone marrow arrest (4/8), hypertension (2/8), proteinuria (3/8), hemoptysis (1/8), nausea (2/8), and fatigue (2/8). Most of these side effects were tolerable.Conclusion:
Apatinib can effectively and tolerably prolong survival time and improve the quality of life of patients with advanced triple-negative breast cancer.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Clinical Oncology
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS